Anti-tumor effect of valorphin in vitro and in vivo: Combined action with cytostatic drugs

Cancer Biology and Therapy

Volumn 4, Issue 1, 2005, Pages 125-131

  Blishchenko, Elena Yu ^a   Sazonova, Olga V ^a   Kalinina, Olga A ^a   Moiseeva, Ekaterina V ^a   Vass, Arpad A ^b   Karelin, Andrey A ^a   Ivanov, Vadim T ^a  

^a SHEMYAKIN OVCHINNIKOV INSTITUTE OF BIOORGANIC CHEMISTRY   (Russian Federation)

^b OAK RIDGE NATIONAL LABORATORY   (United States)

Author keywords

Additive effect; Combinatorial treatment; Cytostatic drug; Endogenous antiproliferative peptide; Epirubicin; Experimental therapy; Lifespan elongation; Valorphin

Indexed keywords

ANTINEOPLASTIC AGENT; DACTINOMYCIN; EPIRUBICIN; HEMOGLOBIN BETA CHAIN; METHOTREXATE; UNCLASSIFIED DRUG; VALYLVALYLTYROSYLPROLYLTRYPTOPHANYLTHREONYLGLUTAMINE; VINCRISTINE; ADAMANTANE; ANTINEOPLASTIC ANTIBIOTIC; DRUG DERIVATIVE; VALORPHIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; ARTICLE; BREAST CARCINOMA; CANCER CELL CULTURE; CANCER INHIBITION; CANCER SURVIVAL; CELL DEATH; CONTROLLED STUDY; DRUG ACTIVITY; FEMALE; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; STATISTICAL SIGNIFICANCE; ANIMAL; ANIMAL DISEASE; BAGG ALBINO MOUSE; BONE MARROW CELL; BREAST TUMOR; CARCINOMA; CELL CULTURE; CELL PROLIFERATION; DRUG EFFECT; DRUG INTERACTION; FIBROBLAST; PATHOLOGY; SURVIVAL;

ADAMANTANE; ANIMALS; ANTIBIOTICS, ANTINEOPLASTIC; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BONE MARROW CELLS; BREAST NEOPLASMS; CARCINOMA; CELL PROLIFERATION; DRUG INTERACTIONS; EPIRUBICIN; FIBROBLASTS; HUMANS; MICE; MICE, INBRED BALB C; SURVIVAL; TUMOR CELLS, CULTURED; VINCRISTINE;

EID: 23744489319     PISSN: 15384047     EISSN: 15558576     Source Type: Journal    
DOI: 10.4161/cbt.4.1.1474     Document Type: Article

References (44)

1. Ivanov VT, Blishchenko EYU, Sazonova OV, Karelin AA. What to synthesize? From Emil Fischer to Peptidomics. J Peptide Sci 2003; 9:553-62.
2. Blishchenko E, Sazonova O, Surovoy A, Khaidukov S, Sheikine Y, Sokolov D, Freidlin I, Philippova M, Karelin A, Ivanov V. Antiproliferative action of valorphin in cell cultures. J Peptide Sci 2002; 8:438-52.
3. Potmesil M, Israel M, Silber R. Two mechanisms of adriamycin-DNA interaction in L1210 cells. Biochem Pharmacol 1984; 33:3137-42.
4. Chuang RY, Chuang LF. Inhibition of chicken myeloblastosis RNA polymerase II activity by adriamycin. Biochemistry 1979; 18:2069-73.
5. Sieber SM, Mead JA, Adamson RH. Pharmacology of antitumor agents from higher plants. Cancer Treat Rep 1976; 60:1127-39.
6. Brantl V, Gramsch CH, Lottspeich F, Mertz R, Jaeger K-H, Herz A. Novel opioid peptides derived from hemoglobin: Hemorphins. Eur J Pharmacol 1986; 125:309-10.
7. Davis TP, Gillespie TJ, Porreca F. Peptide fragments derived from the β-chain of hemoglobin (hemorphins) are centrally active in vivo. Peptides 1989; 10:747-51.
8. Erchegyi J, Kastin AJ, Zadina JE, Qiu X-D. Isolation of a heptapeptide Val-Val-Tyr-ProTrp-Thr-Gln (valorphin) with some opiate activity. Int J Pept Prot Res 1992; 39:477-84.
9. Zhao Q, Piot JM, Sannier F, Guillochon D. Peptic hemoglobin hydrolysis in an ultrafiltration reactor at pilot plant scale generates opioid peptides. Ann NY Acad Sci 1995; 750:452-8.
10. Blishchenko E, Mernenko O, Mirkina L, Satpaev D, Ivanov V, Tchikin L, Ostrovsky A, Karelin A, Ivanov V. Tumor cell cytolysis mediated by valorphin, an opioid-like fragment of hemoglobin β-chain. Peptides 1997; 18:79-85.
11. Ivanov VT, Karelin AA, Blishchenko EY, Philippova MM, Nazimov IV. Proteolytic degradation of hemoglobin in vivo. Role in formation of tissue-specific peptide pool. Pure Appl Chem 1998; 70:67-74.
12. Karelin A, Phillipova M, Yatskin O, Kalinina O, Nazimov I, Blishchenko E, Ivanov V. Peptides comprising the bulk of rat brain extracts: Isolation, amino acid sequences and biologecal activity. J Peptide Sci 2000; 6:345-54.
13. Blishchenko E, Sazonova O, Kalinina O, Yatskin O, Philippova M, Surovoy A, Karelin A, Ivanov V. Family of Hemorphins: Corelations between amino acid sequences and effects in cell cultures. Peptides 2002; 23:903-10.
14. Zagon I, Hytrek S, McLaughlin P. Opioid growth factor tonically inhibits human colon cancer cell proliferation in tissue culture. Am J Physiol 1996; 271:511-8.
15. McLaughlin PJ, Zagon IS, Skitzki J. Human neuroblastoma cell growth in tissue culture is regulated by opioid growth factor. Int J Oncol 1999; 14:373-80.
16. Bisignani GJ, McLaughlin PJ, Ordille SD, Beltz MS, Jarowenko MV, Zagon IS. Human renal cell cancer proliferation in tissue culture is tonically inhibited by opioid growth factor. J Urol 1999; 162:2180-91.
17. Zagon IS, Smith JP, McLaughlin PJ. Human pancreatic cancer cell proliferation in tissue culture is tonically inhibited by opioid growth factor. Int J Oncol 1999; 14:577-84.
18. Gembitsky D, Reichelt K, Elgjo K. Antiproliferative effect of the tripeptide pyroGlu-Phe-GlyNH2 on murine melanocytes: Transitory delay of cell growth in vitro and the cell cycle specificity. Exp Cell Res 1998; 243:367-74.
19. Elgjo K, Reichelt K, Gembitsky DS. Growth-inhibiting N-substituted endogenous peptides. Prog Mol Subcell Biol 1998; 20:143-59.
20. Jackson J, Yan Y, Ewel C, Talmadge J. Activity of acetyl-N-Ser-Asp-Lys- Pro (AcSDKP) on hematopoietic progenitor cells in short-term and long-term murine bone marrow cultures. Exp Hematol 1996; 24:475-81.
21. Gembitsky D, Popova N, Antokhin A, Podusov Y, Karpets L, Adrianov N, Romanov Y. The Ehrlich ascites carcinoma (EAC) contains 300-500 Da inhibitor(s) suppressing DNA synthesis in cultured EAC cells and EAC cell division in tumor-bearing mice. Oncol Rep 1996; 3:333-8.
22. Gembitsky D, Reichelt K, Haakonsen P, Paulsen J, Elgjo K. Identification of a melanocyte growth-inhibiting tripeptide and determination of its structure. J Pept Res 1998; 51:80-84.
23. Gembitsky D, De Angelis P, Reichelt K, Elgjo K. An endogenous melanocyte-inhibiting tripeptide pyroGlu-Phe-GlyNH2 delays in vivo growth of monoclonal experimental melanoma. Cell Prolif 2000; 33:91-9.
24. Marshall G, Merrifield R. In: Stakk GK, ed. Biochemical aspects of reactions on solid supports. New York: Academic press, 1971.
25. Vodovozova E, Moiseeva E, Grechko G, Gayenko G, Nifant'ev N, Bovin N, Molotkovsky J. Atitumour activity of cytotoxic liposomes, equipped with selectin ligand SiaLeX, in mouse mammary adenocarcenoma. Eur J Cancer 2000; 36:942-9.
26. Tsyrlova I, Wolpe S. Hemoglobin α- and β-chain fragments useful for inhibiting of stem cell proliferation. US patent #6,090,782, 2000.
27. Maneckjee R, Biswas R, Vonderhaar BK. Binding of opioids to human MCF-7 breast cancer cells and their effects on growth. Cancer Res 1990; 50:2234-8.
28. Hatzoglou A, Bakogeorgou E, Castanas E. The antiproliferative effect of opioid receptor agonists on the T47D human breast cancer cell line, is partially mediated through opioid receptors. Eur J Pharmacol 1996; 296:199-207.
29. Venihaki M, Gravanis A, Margioris AN. Kappa opioids exert a strong antiproliferative effect on PC12 rat pheochromocytoma cells. Peptides 1996; 17:413-9.
30. Shahabi NA, Sharp BM. Antiproliferative effects of delta opioids on highly purified CD4+ and CD8+ murine T cells. J Pharmacol Exp Ther 1995; 273:1105-13.
31. Agarwal D, Glasel JA. Hormone-defined cell system for studying G-protein coupled receptor agonist-activated growth modulation: Delta-opioid and serotonin-5HT2C receptor activation show opposite mitogenic effects. J Cell Physiol 1997; 171:61-74.
32. 2+-dependent secretion in human small-cell lung carcinoma cells. J Neurosci 1996; 16:3672-84.
33. Hatzoglou A, Bakogeorgou E, Kampa M, Panagiotou S, Martin P, Loukas S, Castanas E. Somatostatin and opioid receptors in mammary tissue. Role in cancer cell growth. Adv Exp Med Biol 2000; 480:55-63.
34. Chaturvedi K, Bandari P, Chinen N, Howells RD. Proteasome involvement in agonist-induced down-regulation of mu and delta opioid receptors. J Biol Chem 2001; 276:12345-55.
35. Fine RL, Chambers TC, Sachs CW. P-Glycoprotein, multidrug resistance and protein kinase C. Oncologist 1996; 1:261-8.
36. Spitaler M, Wiesenhofer B, Biedermann V, Seppi T, Zimmermann J, Grunicke H, Hofmann J. The involvement of protein kinase C isoenzymes α, ε and ζ in the sensitivity to antitumor treatment and apoptosis induction. Anticancer Res 1999; 19:3969-76.
37. Goodfellow H, Sardini A, Ruetz S, Callaghan R, Gros P, McNaughton P, Higgins C. Protein kinase C-mediated phosphorylation does not regulate drug transport by the human multidrug resistance P-glycoprotein. J Biol Chem 1996; 271:13668-74.
38. Ma Q, Zhang ZS, Zhang YL, Wang QY, Lai ZS. Effect of protein kinase C on multidrug resistance of multidrug-resistant colorectal cancer LoVo/Adr cells. Di Yi Jun Yi Da Xue Xue Bao 2002; 22:626-8.
39. Sharp BM. Opioid receptor expression and intracellular signaling by cells involved in host defense and immunity. Adv Exp Med Biol 2003; 521:98-105.
40. Hucklebridge FH, Hudspith BN, Lydyard PM, Brostoff J. Stimulation of human peripheral lymphocytes by methionine enkephalin and Δ-selective opioid analogues. Immunopharmacology 1990; 19:87-91.
41. Khabarov SV, Gerasimova GK, Mikhailova AA, Petrov RV. Myelopeptide-2 induces the resistance of T-lymphocytes to tumor suppression. Dokl Biol Sci 2003; 390:282-5.
42. Scholar EM, Violi L, Hexum TD. The antimetastatic activity of enkephalin-like peptides. Cancer Lett 1987; 35:133-8.
43. Thomas J, Arzoomanian R, Alberti D, Marnocha R, Lee F, Friedl A, Tutsch K, Dresen A, Geiger P, Pluda J, Fogler W, Schiller J, Wilding G. Phase I pharmacokinetic and pharmacodynamic study of recombinant human endostatin in patients with advanced solid tumors. J Clin Oncol 2003; 21:223-31.
44. Liebmann C, Schrader U, Brantl V. Opioid receptor affinities of the blood-derived tetrapeptides hemorphin and cytochrophin. Eur J Pharmacol 1989; 166:523-6.